<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04987554</url>
  </required_header>
  <id_info>
    <org_study_id>2020.08.10</org_study_id>
    <nct_id>NCT04987554</nct_id>
  </id_info>
  <brief_title>Glycophosphopeptical AM3 A Potential Adjuvant in the Treatment of SARS-CoV-2</brief_title>
  <official_title>Modulation of the Immune Response by AM3 Glycoconjugate.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Valladolid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanidad de Castilla y León</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Valladolid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: In late 2019, a novel human coronavirus was detected in Wuhan, China, causing&#xD;
      an outbreak of the severe acute respiratory syndrome - Coronavirus 2 (SARS-CoV-2). The&#xD;
      disease that SARS-CoV-2 causes was named coronavirus disease 2019 (COVID-19). The virus&#xD;
      rapidly spread throughout China and beyond, causing a public health challenge of global&#xD;
      concern. Today, the availability of safe and effective drugs to treat COVID-19 remains&#xD;
      limited, and symptomatic supportive treatments are the foundations of care. A natural&#xD;
      glycophosphopeptical, AM3 has been shown to effectively improve the progression of infectious&#xD;
      respiratory diseases with no side effects. In this context, AM3 could maintain an adequate&#xD;
      immune status and serve as a therapeutic tool against COVID-19.&#xD;
&#xD;
      Study Aim: The effect of AM3 supplementation on the progression of COVID-19 patients. To&#xD;
      evaluate the existence of significant differences between control and intervention groups in&#xD;
      the progression of severe COVID-19 disease.&#xD;
&#xD;
      Methods: Double-blind randomized controlled clinical trial in collaboration with the Health&#xD;
      Care Management of Soria. At the start of the trial, eligible patients will be randomized in&#xD;
      a 1:1 ratio into two intervention and control groups. Block randomization with participants&#xD;
      based on gender will be used. 120 patients with a confirmed diagnosis of COVID-19 by PCR&#xD;
      and/or antigen testing will be randomized to the control group (placebo treatment) or&#xD;
      experimental group (AM3 treatment), respectively. Patients will be randomly divided into two&#xD;
      groups, the AM3 supplementation group (n=60) and the control group (n=60). The intervention&#xD;
      group will be administered 2 indistinct capsules of AM3 (3 g/day of AM3) for 30 consecutive&#xD;
      days, distributed in a single daily oral intake in the morning on an empty stomach. The&#xD;
      control group will be administered a placebo of identical appearance of 2 indistinct capsules&#xD;
      for a single daily intake in the morning, same dose as the experimental group (3 g/day of&#xD;
      placebo), for 30 consecutive days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lactato deshidrogenasa (LDH)</measure>
    <time_frame>1day</time_frame>
    <description>a catalytic enzyme found in many tissues of the body</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lactato deshidrogenasa (LDH)</measure>
    <time_frame>30 days</time_frame>
    <description>a catalytic enzyme found in many tissues of the body</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Creatine kinase (CK)</measure>
    <time_frame>1day and 30 days</time_frame>
    <description>CK is an enzyme expressed by various tissues and cell types.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myoglobin (Mb)</measure>
    <time_frame>1day and 30 days</time_frame>
    <description>Mb is a muscle heteroprotein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase (AST)</measure>
    <time_frame>1day and 30 days</time_frame>
    <description>markers of liver damage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase (ALT)</measure>
    <time_frame>1day and 30 days</time_frame>
    <description>markers of liver damage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 6 (IL-6)</measure>
    <time_frame>1day and 30 days</time_frame>
    <description>inflammatory marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 1β (IL-1β)</measure>
    <time_frame>1day and 30 days</time_frame>
    <description>inflammatory marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tumor necrosis factor (TNF-α)</measure>
    <time_frame>1day and 30 days</time_frame>
    <description>inflammatory marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tumor necrosis factor receptor (TNFR-α)</measure>
    <time_frame>1day and 30 days</time_frame>
    <description>inflammatory marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein (CRP)</measure>
    <time_frame>1day and 30 days</time_frame>
    <description>inflammatory marker; acute phase reactants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ferritin (FER)</measure>
    <time_frame>1day and 30 days</time_frame>
    <description>Fer is a protein that stores iron in the cells; acute phase reactants - inflammatory marker</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>AM3 supplementation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 capsules for 30 consecutive days, distributed in a single daily oral intake in the morning on an empty stomach.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 capsules for 30 consecutive days, distributed in a single daily oral intake in the morning on an empty stomach.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>glycophosphopeptical AM3</intervention_name>
    <description>3 g/day of AM3</description>
    <arm_group_label>AM3 supplementation group</arm_group_label>
    <other_name>Inmunoferon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3 g/day of placebo</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years&#xD;
&#xD;
          -  Males and females&#xD;
&#xD;
          -  Confirmed clinical diagnosis of COVID-19 positive by Real-Time Reverse Transcription&#xD;
             Polymerase Chain Reaction (RT-PCR) and/or SARS-CoV-2 Antigen Test performed 120 hours&#xD;
             prior to patient inclusion in the study&#xD;
&#xD;
          -  LDH 250-400 U/L&#xD;
&#xD;
          -  Acceptance of informed consent signature&#xD;
&#xD;
          -  IMC: 18.5-30&#xD;
&#xD;
          -  Patients not participating in other trials&#xD;
&#xD;
          -  No hepatic and renal disorders&#xD;
&#xD;
          -  Possession of mental faculties to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with rare and specific viral diseases such as HIV&#xD;
&#xD;
          -  Patients undergoing chemotherapy during the last 2 months&#xD;
&#xD;
          -  Any other condition/pathology diagnosed by the medical specialist that prevents them&#xD;
             from participating in the trial&#xD;
&#xD;
          -  Intake of vitamin complexes or functional foods&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Diego Fernández, Professor PhD</last_name>
    <phone>+34975129185</phone>
    <phone_ext>9185</phone_ext>
    <email>diego.fernandez.lazaro@uva.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cesar Ignacio Fernández Lázaro, PhD</last_name>
    <phone>+34615152130</phone>
    <email>fernandezlazaro@usal.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro de Salud &quot;La Milagrosa&quot; Soria Sur</name>
      <address>
        <city>Soria</city>
        <zip>42003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diego M Fernández Lázaro, PhD</last_name>
      <phone>658073375</phone>
      <email>diego.fernandez.lazaro@uva.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Valladolid</investigator_affiliation>
    <investigator_full_name>Diego Fernandez Lazaro</investigator_full_name>
    <investigator_title>Professor Doctor</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>AM3</keyword>
  <keyword>treatment</keyword>
  <keyword>immunomodulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoferon</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

